Epstein Barr Virus News and Research

Latest Epstein Barr Virus News and Research

Damon Runyon Cancer Research Foundation announces newest cohort of Fellows and Breakthrough Scientists

The Damon Runyon Cancer Research Foundation has announced its newest cohort of Damon Runyon Fellows, 13 outstanding postdoctoral scientists conducting basic and translational cancer research in the laboratories of leading senior investigators.

29 Jan 2022

Study identifies a new potential pathway for developing therapeutics against Epstein-Barr virus

A new study by researchers at The Wistar Institute, an international biomedical research leader in cancer, immunology, infectious disease, and vaccine development, has identified a new potential pathway for developing therapeutics that target Epstein-Barr virus (EBV).

19 Jan 2022

Study provides insights into how SARS-CoV-2 impacts the brain

Some patients who develop new cognitive symptoms after a mild bout of COVID have abnormalities in their cerebrospinal fluid similar to those found in people with other infectious diseases.

18 Jan 2022

Multiple sclerosis may be caused by infection with the Epstein-Barr virus

Multiple sclerosis (MS), a progressive disease that affects 2.8 million people worldwide and for which there is no definitive cure, is likely caused by infection with the Epstein-Barr virus (EBV), according to a study led by Harvard T.H. Chan School of Public Health researchers.

13 Jan 2022

SARS-CoV-2 Delta binds more strongly to furin protease than other existing variants

Researchers conducted a computational analysis of the furin cleavage domain (FCD) of SARS-CoV-2 and its variants, as well as several other viruses.

10 Jan 2022

Moderna announces initiation of Phase 1 study of its mRNA-1189 EBV vaccine candidate

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, today announced the first participant has been dosed in the Phase 1 study of mRNA-1189, the Company's Epstein-Barr Virus vaccine candidate.

7 Jan 2022

Wistar announces initiation of Phase 2 clinical study of VK-2019 in patients with advanced head and neck cancer

The Wistar Institute announces the initiation of a Phase 2 clinical study of VK-2019 in patients with advanced Epstein-Barr Virus (EBV)-positive nasopharyngeal carcinoma (NPC) and lymphoma.

5 Jan 2022

Pacific oyster as a weapon against SARS-CoV-2

According to an article published in the journal Reviews in Medical Virology, the effectiveness of mollusc-derived antiviral agents has been proven in many different laboratory and animal studies, while its efficacy against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has also been proposed by recent in silico studies.

7 Nov 2021

Study shows immune profile heterogeneity amongst healthy adults

Researchers opted to use single-cell RNA-seq to observe single cells in detail as they encounter a specific antigen.

22 Oct 2021

Epstein-Barr virus reactivation may play a role in long COVID and severe COVID-19 cases

Two recently published studies available on the National Institutes of Health website indicate Epstein-Barr virus (EBV) reactivation may play a role both in the development of long COVID symptoms, as well as severe COVID-19 cases.

22 Jul 2021

SARS-CoV-2 test in 20 minutes with FISH

A collaboration from the University of Oxford and the University of Warwick has led to research into a novel method of viral detection through rapid fluorescence in situ hybridization (FISH) in order to effectively detect the SARS-CoV-2 virus within 20 minutes.

29 Jun 2021

Epstein-Barr virus reactivation may be the cause of long COVID symptoms

Epstein-Barr virus (EBV) reactivation resulting from the inflammatory response to coronavirus infection may be the cause of previously unexplained long COVID symptoms -- such as fatigue, brain fog, and rashes -- that occur in approximately 30% of patients after recovery from initial COVID-19 infection.

23 Jun 2021

New research uncovers substantial differences in rates of childhood cancers

New research uncovers substantial differences in rates of childhood cancers when considering single year of age rather than grouping several years together.

21 Jun 2021

Novel method allows rapid, absolute quantification of viral nucleic acids

Researchers from Critical Analytics for Manufacturing Personalized-Medicine, an Interdisciplinary Research Group at the Singapore-MIT Alliance for Research and Technology, MIT's research enterprise in Singapore, have developed a new method for rapid and accurate detection of viral nucleic acids - a breakthrough that can be easily adapted to detect different DNA/RNA targets in viruses like the coronavirus.

7 Jun 2021

Corilagin: could a plant compound used in Chinese herbal medicine help prevent COVID-19?

The study, published in the journal Phytomedicine, characterized an active compound, corilagin (a derivative from Phyllanthus urinaria), as potential SARS-CoV-2 entry inhibitors for its preventive application in daily antiviral hygiene products.

31 May 2021

Neurocognitive symptoms persist 6 months post-infection with long COVID

According to the World Health Organization (WHO), COVID-19 long-haulers are people who experience symptoms such as body ache, fatigue, shortness of breath, headache, difficulty concentrating, loss of taste or smell, or other health issues long after they test negative for the virus. It can be defined as having serious and prolonged symptoms three months after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

26 May 2021

Nanoparticle (SpFN) vaccine candidate elicits multifactorial cellular immune responses against SARS-CoV-2 in vivo

Researchers have developed a promising new anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)vaccine candidate that utilizes nanotechnology and shows robust, long-lived immunity in mouse models.

5 May 2021

Class I HLA alleles shape CD8+ T cell repertoire in SARS-CoV-2 infection

An interesting new study discusses how adaptive cellular immunity against the SARS-CoV-2 is dependent on differences in HLA-encoding genes between patients.

3 May 2021

Curcumin nanosystems could be powerful COVID-19 therapeutics

With new variants of SARS-CoV-2 emerging, the COVID-19 pandemic is far from over. While the global vaccine rollout has moved at an impressive speed, the search for new safe, effective, and targeted therapies is still on. Now, a new study reviews the potential for curcumin, a natural alkaloid derived from turmeric, and nanosystems to treat COVID-19.

16 Apr 2021

Coronavirus deranges the immune system in complex and deadly ways

There's a reason soldiers go through basic training before heading into combat: Without careful instruction, green recruits armed with powerful weapons could be as dangerous to one another as to the enemy.

4 Mar 2021

Epstein Barr Virus News and Research

Latest Epstein Barr Virus News and Research

Damon Runyon Cancer Research Foundation announces newest cohort of Fellows and Breakthrough Scientists

Study identifies a new potential pathway for developing therapeutics against Epstein-Barr virus

Study provides insights into how SARS-CoV-2 impacts the brain

Multiple sclerosis may be caused by infection with the Epstein-Barr virus

SARS-CoV-2 Delta binds more strongly to furin protease than other existing variants

Moderna announces initiation of Phase 1 study of its mRNA-1189 EBV vaccine candidate

Wistar announces initiation of Phase 2 clinical study of VK-2019 in patients with advanced head and neck cancer

Pacific oyster as a weapon against SARS-CoV-2

Study shows immune profile heterogeneity amongst healthy adults

Epstein-Barr virus reactivation may play a role in long COVID and severe COVID-19 cases

SARS-CoV-2 test in 20 minutes with FISH

Epstein-Barr virus reactivation may be the cause of long COVID symptoms

New research uncovers substantial differences in rates of childhood cancers

Novel method allows rapid, absolute quantification of viral nucleic acids

Corilagin: could a plant compound used in Chinese herbal medicine help prevent COVID-19?

Neurocognitive symptoms persist 6 months post-infection with long COVID

Nanoparticle (SpFN) vaccine candidate elicits multifactorial cellular immune responses against SARS-CoV-2 in vivo

Class I HLA alleles shape CD8+ T cell repertoire in SARS-CoV-2 infection

Curcumin nanosystems could be powerful COVID-19 therapeutics

Coronavirus deranges the immune system in complex and deadly ways

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Epstein Barr Virus News and Research

Latest Epstein Barr Virus News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in